

Oviva Tier 3 Eligibility Criteria

NHS North East London ICB



Inclusion criteria



- Age at least 18 years old
- Patients should only be referred for treatment if they meet **ALL** the below eligibility criteria:

Criteria 1) BMI Criteria (-2.5kg/m² for ethnic minorities):

- **BMI ≥ 35 kg/m² or**
- **BMI 30.0 - 34.9 kg/m² and** meet the criteria for referral to specialist overweight and obesity management services, where:
 - the underlying causes of overweight or obesity need to be assessed
 - person has complex diseases states or needs that cannot be managed adequately in behavioural overweight & obesity management services (e.g the extra support needs of people with learning disabilities)- less intensive management has been unsuccessful
 - specialist interventions (such as a very-low-calorie diet, surgery or certain medicines) are being considered

Criteria 2) At least **ONE** weight-related co-morbidity (**complete list**):

- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Cardiovascular disease

Criteria 3) Supportive management

- Patient must agree to a sustained programme of lifestyle interventions, including reduced calorie diet and increased physical activity with advice and management.

Exclusion Criteria



- Patients under 18 years old.
- Patients who are currently successfully losing weight with dietetic or reputable evidence-based weight management intervention.
- Patients who are pregnant, planning pregnancy or breastfeeding.
- Patients who have been previously referred into the service and have left the pathway early or have disengaged from the services, who are seeking to re-enter as a re-referral will not be eligible within 12 months.
- Patients with uncontrolled hypertension/heart condition/medical condition preventing increase in activity level.
- Patient with untreated or unstable major mental illness.
- Patients with active eating disorders.
- Patients who have made suicide attempts within the last year.
- Patients who have self-harmed in the past 3 months.
- Patients who have made plans to commit suicide in the past 3 months.
- Patients with alcohol dependence (regardless of whether they are under an alcohol dependency programme).
- Patients who have had bariatric surgery.
- Patients with known hypersensitivity to semaglutide or tirzepatide or their excipients.
- Patients with known severe hypersensitivity reactions such as anaphylaxis and angioedema, to another GLP-1 receptor agonist (e.g liraglutide, dulaglutide, exenatide, lixisenatide).
- Patients with personal or family history of medullary thyroid carcinoma (MTC).
- Patients with history of multiple endocrine neoplasia syndrome type 2 (MEN2).
- Patients with history of current, recent (within 6 months), chronic or recurrent pancreatitis.
- Patients with decompensated liver cirrhosis.

